Agios Pharmaceuticals AGIO Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$422.6M-2.4% | -$412.78M— | —— | —— | —— | ||
| $5.26M+1.6% | $5.18M-1.9% | $5.28M+0.6% | $5.25M-6.0% | $5.58M-1.2% | ||
| $56.73M+8.0% | $52.55M+6.5% | $49.33M+2.6% | $48.1M+7.0% | $44.97M+5.0% | ||
| $12.79M+97.7% | $6.47M+238% | $1.91M— | —— | —— | ||
| $5.48M+3.4% | $5.3M-5.4% | $5.61M-18.9% | $6.91M+5.8% | $6.54M-23.5% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | -$4.37M-218% | ||
| —— | —— | —— | $10.04M+161% | $3.84M-33.8% | ||
| —— | —— | —— | —— | —— | ||
| $12.67M+1.9% | $12.43M+1.9% | $12.19M+1.9% | $11.97M+1.9% | $11.75M+1.9% | ||
| -$17.2M-2.5% | -$16.78M-2.8% | -$16.32M-2.9% | -$15.86M-2.9% | -$15.41M-2.7% | ||
| -$380.41M-2.0% | -$372.98M+9.0% | -$409.93M-1.0% | -$406M-1.1% | -$401.46M-3.0% | ||
| $4.32M+0.1% | $4.32M+3.7% | $4.16M+37.5% | $3.03M+31.0% | $2.31M+37.1% | ||
| $615.04M-4.2% | $641.76M-5.5% | $679.01M-54.7% | $1.5B+1.8% | $1.47B-4.5% | ||
| $1.04B+0.2% | $1.03B+11.0% | $931.12M+14.0% | $816.61M+10.7% | $737.92M-9.8% | ||
| $405.91M+7.6% | $377.18M— | —— | —— | —— | ||
| $9.14M+5.3% | $8.68M-20.8% | $10.96M+19.6% | $9.16M-10.1% | $10.2M-29.4% | ||
| $9.14M+5.3% | $8.68M-20.8% | $10.96M+19.6% | $9.16M-10.1% | $10.2M-29.4% | ||
| —— | —— | -$161.02M-4,315% | -$3.65M+90.8% | -$39.8M-233% | ||
| —— | —— | $45.36M+0.2% | $45.26M+3.2% | $43.86M+1.7% | ||
| $6.99M-2.8% | $7.2M-34.9% | $11.06M-15.7% | $13.12M-1.4% | $13.31M-8.1% | ||
| —— | —— | —— | —— | -$4.37M-218% | ||
| -$17.2M-2.5% | -$16.78M-2.8% | -$16.32M-2.9% | -$15.86M-2.9% | -$15.41M-2.7% | ||
| —— | —— | —— | $10.04M+161% | $3.84M-33.8% | ||
| $12.67M+1.9% | $12.43M+1.9% | $12.19M+1.9% | $11.97M+1.9% | $11.75M+1.9% | ||
| $5.26M+1.6% | $5.18M-1.9% | $5.28M+0.6% | $5.25M-6.0% | $5.58M-1.2% | ||
| $144K+22.0% | $118K— | $0-100% | $17K-5.6% | $18K-89.3% | ||
| $1.04B+0.2% | $1.03B+11.0% | $931.12M+14.0% | $816.61M+10.7% | $737.92M-9.8% | ||
| $9.14M+5.3% | $8.68M-20.8% | $10.96M+19.6% | $9.16M-10.1% | $10.2M-29.4% | ||
| —— | —— | —— | —— | $538K+69.7% | ||
| -$17.2M-2.5% | -$16.78M-2.8% | -$16.32M-2.9% | -$15.86M-2.9% | -$15.41M-2.7% | ||
| —— | —— | $45.36M+0.2% | $45.26M+3.2% | $43.86M+1.7% | ||
| -$384.73M-2.0% | -$377.29M+8.9% | -$414.09M-1.2% | -$409.03M-1.3% | -$403.77M-3.1% | ||
| -$384.73M-2.0% | -$377.29M+8.9% | -$414.09M-1.2% | -$409.03M-1.3% | -$403.77M-3.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Agios Pharmaceuticals generate?
- Agios Pharmaceuticals (AGIO) generated -$380.4M in operating cash flow over the trailing twelve months.
- What is Agios Pharmaceuticals's free cash flow?
- After $4.3M of capital expenditures, Agios Pharmaceuticals's free cash flow was -$384.7M over the trailing twelve months, up 4.7% year over year.
- Where does Agios Pharmaceuticals's cash flow data come from?
- Every line is extracted from Agios Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
